Legislative Trackers
-
S 772
Introduced 2025-02-27A summary is in progress. -
HR 1801
Introduced 2025-03-03A summary is in progress. -
HR 1662
Introduced 2025-02-27A summary is in progress. -
HR 2732
Introduced 2025-04-08A summary is in progress. -
HR 1776
Introduced 2025-03-03A summary is in progress. -
HR 1859
Introduced 2025-03-05A summary is in progress. -
S 1820
Introduced 2025-05-20A summary is in progress. -
HR 3907
Introduced 2025-06-11A summary is in progress. -
S 1716
Introduced 2025-05-12A summary is in progress. -
HR 20
Introduced 2025-03-05A summary is in progress. -
S 2024
Introduced 2025-06-11A summary is in progress. -
HR 3662
Introduced 2025-05-29A summary is in progress. -
HR 247
Introduced 2025-01-09A summary is in progress. -
S 758
Introduced 2025-02-26A summary is in progress. -
HR 317
Introduced 2025-01-09A summary is in progress. -
S 852
Introduced 2025-03-05A summary is in progress. -
S 1710
Introduced 2025-05-12A summary is in progress. -
S 770
Introduced 2025-02-27A summary is in progress. -
HR 919
Introduced 2025-02-04Chronic Disease Flexible Coverage Act
This bill provides statutory authority for guidance from the Internal Revenue Service (IRS) that expands the types of preventive care that may be offered under a high deductible health plan (HDHP) without requiring a deductible or with a deductible below the minimum threshold.
Under current law, to be considered health savings account-eligible, an HDHP must have a deductible above a certain minimum threshold amount, which is adjusted annually. However, an HDHP may cover certain types of preventive care without requiring a deductible or with a deductible below the minimum threshold.
The IRS issued guidance expanding the types of preventive care that may be covered by an HDHP without requiring a deductible or with a deductible below the minimum threshold to include
- angiotensin converting enzyme inhibitors for individuals with congestive heart failure, diabetes, or coronary artery disease;
- anti-resorptive therapy for individuals with osteoporosis or osteopenia;
- beta-blockers for individuals with congestive heart failure or coronary artery disease;
- blood pressure monitors for individuals with hypertension;
- inhaled corticosteroids and peak flow meters for individuals with asthma;
- insulin and other glucose lowering agents, retinopathy screening, glucometers, and hemoglobin A1c testing for individuals with diabetes;
- international normalized ratio testing for individuals with liver disease or bleeding disorders;
- low-density lipoprotein testing for individuals with heart disease;
- statins for individuals with heart disease or diabetes; and
- selective serotonin reuptake inhibitors for individuals with depression.
The bill provides statutory authority for the IRS's guidance.
-
S 529
Introduced 2025-02-11A summary is in progress.